BiomX Inc. (NYSEAMERICAN:PHGE) Sees Large Increase in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 623,734 shares, an increase of 83.3% from the August 15th total of 340,328 shares. Based on an average daily volume of 1,058,843 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.3% of the company’s stock are short sold.

BiomX Stock Performance

NYSEAMERICAN:PHGE remained flat at $1.85 on Thursday. 3,333,670 shares of the company’s stock traded hands, compared to its average volume of 364,372. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 0.02. The firm has a market cap of $4.94 million, a PE ratio of -0.58 and a beta of 1.33. BiomX has a 52-week low of $1.19 and a 52-week high of $122.93. The firm’s 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $14.70.

BiomX (NYSEAMERICAN:PHGE) last announced its earnings results on Wednesday, August 19th. The company reported ($3.70) earnings per share for the quarter. The firm had revenue of $0.33 million during the quarter. Equities research analysts predict that BiomX will post -58.5 EPS for the current year.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.